Staar Surgical Co. Stock
€35.78
Your prediction
Staar Surgical Co. Stock
Pros and Cons of Staar Surgical Co. in the next few years
Pros
Cons
Performance of Staar Surgical Co. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Staar Surgical Co. | -2.610% | -6.531% | -16.186% | -25.845% | 23.252% | -69.129% | - |
Orasure Tech | 3.770% | 2.326% | -12.871% | -13.725% | -40.940% | -41.937% | -40.605% |
scPharmaceuticals | 12.900% | 13.514% | -3.226% | -59.615% | -26.957% | -12.863% | - |
SI-BONE Inc | 2.400% | 4.065% | -3.030% | -50.000% | -32.632% | -51.145% | - |
Comments
News
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites
STAAR Surgical Reports First Quarter 2024 Results
STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today